Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on A...
April 14 2021 - 4:06PM
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study
in Poster Session at 2021 Virtual AAN Annual Meeting on April
17-22, 2021
Biogen (Nasdaq: BIIB) today announced it will host a poster
presentation on the design of the EMBARK trial of its Alzheimer’s
disease investigational therapy, aducanumab, at the upcoming 2021
virtual American Academy of Neurology (AAN) Annual Meeting.
AAN Poster Presentation Details:
- Saturday, April 17, 2021, 8:00 a.m. ET – EMBARK: A Phase 3b,
open-label, single-arm, safety study to evaluate the long-term
safety and efficacy of aducanumab in eligible participants with
Alzheimer’s disease with Carmen Castrillo-Viguera, M.D., Senior
Medical Director, Clinical Development at Biogen
To access the poster presentation, please go to the Investors
section of Biogen’s website at investors.biogen.com. Following the
event, an archived version will be available on the website.
About BiogenAt Biogen, our mission is clear: we
are pioneers in neuroscience. Biogen discovers, develops and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp. Today Biogen has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, Alzheimer’s disease and dementia, neuromuscular
disorders, movement disorders, ophthalmology, neuropsychiatry,
immunology, acute neurology and neuropathic pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. To learn more, please visit
www.biogen.com and follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
About AducanumabAducanumab (BIIB037) is an
investigational human monoclonal antibody studied for the treatment
of Alzheimer’s disease. Based on clinical data from patients with
Mild Cognitive Impairment due to Alzheimer’s disease and mild
Alzheimer’s disease, aducanumab has the potential to impact
underlying disease pathophysiology, slow cognitive and functional
decline and provide benefits on patients’ ability to perform
activities of daily living, including conducting personal finances,
performing household chores, such as cleaning, shopping and doing
laundry, and independently traveling out of the home. If approved,
aducanumab would be the first treatment to meaningfully change the
course of the disease for individuals living with Alzheimer’s.
Biogen licensed aducanumab from Neurimmune under a collaborative
development and license agreement. Since October 2017 Biogen and
Eisai have collaborated on the development and commercialization of
aducanumab globally.
MEDIA CONTACT:David Caouette
+1 617 679
4945public.affairs@biogen.com |
INVESTOR CONTACT:Mike Hencke+1 781 464 2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024